Spontaneous onset of labour · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
Amniotic membranes sweeping showed no clear difference in spontaneous onset of labour compared with vaginal/intracervical prostaglandins (low certainty).
1 finding from 1 review
Induction of labour · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
Amniotic membranes sweeping showed no clear difference in induction of labour compared with vaginal/intracervical prostaglandins (low certainty).
1 finding from 1 review
Intervention not reported
Fatal injuries — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐fatal injuries — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Non‐injury accidents — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Absenteeism — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events associated with RAT — not measured · Workers in positions with safety‐sensitive functions, other than commercial drivers
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Children and older adults treated with SDF for carious lesions
No serious adverse events (e.g., allergic reactions or toxicity) were reported for SDF across the reviews (ungraded).
1 finding from 1 review
Adverse events: black staining of arrested lesions · Children and older adults treated with SDF for carious lesions
Black staining of arrested lesions was the main adverse event of SDF (reported by seven reviews); it was generally acceptable to patients (ungraded).
1 finding from 1 review
Low birthweight · women at increased risk of low birthweight babies (maternal outcomes)
Additional support showed no clear difference in birthweight < 2500 g compared with usual care during pregnancy (moderate certainty).
1 finding from 1 review
Gestational age (preterm birth < 37 weeks) · women at increased risk of low birthweight babies (maternal outcomes)
Additional support showed no clear difference in gestational age < 37 weeks at birth compared with usual care during pregnancy (moderate certainty).
1 finding from 1 review
Death of a baby (stillbirth or neonatal death) report of perinatal death · women at increased risk of low birthweight babies (maternal outcomes)
Additional support showed no clear difference in stillbirth/neonatal death compared with usual care during pregnancy (low certainty).
1 finding from 1 review
Assessment of long‐term morbidity · women at increased risk of low birthweight babies (maternal outcomes)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review